Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Predicting etoposide toxicity: relationship to organ function and protein binding

S P Joel1, R Shah, P I Clark

  • 1Department of Medical Oncology, St Bartholomew's Hospital, London, United Kingdom.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|January 1, 1996
PubMed
Summary

Organ dysfunction increases etoposide toxicity by raising free etoposide levels. Dose reduction is recommended for patients with impaired renal or liver function, or low albumin, to mitigate hematologic toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The acceptability of smokeless tobacco products depends on nicotine levels.

Addictive behaviors reports·2019
Same author

Measurement of Coherent π^{+} Production in Low Energy Neutrino-Carbon Scattering.

Physical review letters·2016
Same author

Improving acute care for adolescents and young adults on medical admission units: The interventions that matter.

Acute medicine·2016
Same author

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Longitudinal magnetic resonance imaging reveals striatal hypertrophy in a rat model of long-term stimulant treatment.

Translational psychiatry·2016
Same author

Chronic recurrent multifocal osteomyelitis (CRMO) - advancing the diagnosis.

Pediatric rheumatology online journal·2016

Area of Science:

  • Pharmacology
  • Oncology
  • Clinical Pharmacy

Background:

  • Etoposide is a crucial chemotherapeutic agent.
  • Understanding etoposide pharmacokinetics and toxicity is vital for safe and effective cancer treatment.
  • Organ function significantly influences drug metabolism and elimination.

Purpose of the Study:

  • To investigate how organ function affects etoposide pharmacokinetics (total and free drug levels).
  • To determine the relationship between organ function, etoposide levels, and hematologic toxicity.
  • To provide evidence-based recommendations for etoposide dosing in patients with organ dysfunction.

Main Methods:

  • Seventy-two patients receiving intravenous etoposide were studied.
  • Plasma etoposide concentrations were analyzed using high-performance liquid chromatography (HPLC).

Related Experiment Videos

  • Etoposide protein binding was assessed by ultrafiltration, and free etoposide area under the concentration-time curve (AUC) was calculated.

    • Main Results:

    • Renal impairment led to decreased etoposide clearance, increased total and free etoposide AUC, and heightened hematologic toxicity.
    • Lower albumin levels correlated with increased unbound etoposide, higher free etoposide AUC, and more severe toxicity.
    • In patients with normal organ function, older age was linked to reduced clearance, and elevated liver enzymes showed a trend towards increased free etoposide AUC.

    Conclusions:

    • Elevated hematologic toxicity from etoposide in patients with organ dysfunction is primarily due to increased free etoposide AUC.
    • Dose reduction of etoposide is clearly indicated for patients with impaired organ function.
    • This study highlights the importance of considering organ function for personalized etoposide dosing to minimize toxicity.